Corcept Therapeutics Incorporated (CORT)

業務介紹

科瑞克藥業公司在美國發現、開發和商業化用於治療嚴重代謝性、腫瘤性和神經精神性疾病的藥物。該公司提供Korlym(米非司酮)片作為每日一次的口服藥物,用於治療成人內源性庫欣氏綜合症所致的高血糖,這些患者患有2型糖尿病或葡萄糖耐量降低,且手術失敗或不適合手術。該公司正在開發relacorilant治療庫欣氏綜合症患者;以及將nab-紫杉醇與relacorilant合併用於治療晚期卵巢腫瘤患者的II期臨床試驗,以及治療皮質醇過度。該公司還正在開發選擇性皮質醇調節劑,用於治療轉移性去勢抵抗性前列腺癌患者;用於治療抗精神病藥物誘發的體重增加和其他疾病的選擇性皮質醇調節劑;以及FKBP5基因表達檢測。科瑞克藥業公司於1998年註冊成立,總部位於加州門洛帕克。



Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

公司網址

https://www.corcept.com